Austin, TX - May 14, 2025

Akexis, a leader in innovative cancer therapeutics, proudly announces the publication of a pivotal editorial by Dr. Lingbing Zhang, Founder and Chief Scientific Officer, in the Archives of Clinical and Biomedical Research. The editorial, titled Immunology of Cancer Cachexia, explores the complex immune-driven mechanisms behind cancer cachexia - a debilitating condition affecting nearly 80% of late-stage cancer patients.

Cancer cachexia is a profound and often overlooked syndrome marked by severe weight loss, muscle atrophy, and systemic inflammation. It contributes significantly to patient morbidity and mortality yet remains largely under-addressed in clinical practice. Dr. Zhang’s editorial sheds light on the intricate immunological pathways driving this condition, offering a compelling case for targeted therapeutic intervention.

“Understanding the immunological drivers of cancer cachexia is crucial for developing effective treatments,” said Dr. Lingbing Zhang, Founder and Chief Scientific Officer at Akexis. “This editorial underscores the need for innovative approaches that address the root causes of cachexia, rather than just its symptoms.”

At Akexis, these insights are directly informing the development of novel therapeutics designed to halt and potentially reverse the effects of cancer cachexia. The company's commitment to groundbreaking research aims to transform the standard of care for patients battling this devastating syndrome.

“Dr. Zhang's contribution highlights the critical need for deeper exploration into the immunology of cancer cachexia,” said Dr. Suzanne Kennedy, Chief Executive Officer of Akexis. “This editorial serves as a call to action for the scientific community to prioritize solutions that improve patient outcomes and quality of life.”

The full editorial is available here:
https://cdn.fortunejournals.com/articles/immunology-of-cancer-cachexia.pdf

For further information, please contact:
Cassie Bernhardt
Chief Development Officer
Akexis
Cassie@akexis.com